Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, Makarova et al. found that topical vitamin D3 significantly delayed basal cell carcinoma development in UVR-exposed, BCC-prone mice, while oral vitamin D3 supplements did not prevent carcinogenesis, suggesting a potential role of UV-induced vitamin D3 in inhibiting tumor growth.

This study found that AR-positive breast cancer cell lines are more sensitive to the dual PI3K/mTOR inhibitor NVP-BEZ235 compared to AR-negative cells.

This case report describes a possible association between Vogt-Koyanagi-Harada disease and linear IgA/IgG bullous dermatosis in a 35-year-old Japanese male, though coincidence cannot be ruled out.

In this mouse study, applying a vasoconstrictor before chemotherapy did not create a leukemia sanctuary or significantly impact survival outcomes, suggesting it may not interfere with leukemia treatment.

This article discusses the evaluation of minimal residual disease in childhood acute lymphoblastic leukemia using molecular methods and reports no new findings.

This review found dutasteride to be effective, safe, and well-tolerated for treating symptomatic BPH and provides expert commentary on its use, though the relationship with high-grade prostate cancer remains unclear.

This study demonstrated that de novo designed bifunctional proteins can target and degrade BCL-xL, leading to cell apoptosis, suggesting a new approach to targeted protein degradation therapy.

This study discusses a hypothesis that combining intermittent androgen ablation therapy with finasteride may enhance prostate cancer treatment, though new results from this approach are not yet available.

This study describes a patient with hereditary vitamin D resistant rickets (HVDRR) who, despite having a truncated vitamin D receptor, did not exhibit typical hair or skin abnormalities, suggesting possible compensation via interactions with other proteins.

In this study, peginterferon alfa-2b plus ribavirin therapy in hepatitis C patients was associated with serious adverse drug reactions in 20% of cases, highlighting differences from clinical trial findings.

This case report describes a 12-year-old boy who developed severe shingles with skin erosion and hair loss despite early aciclovir treatment after a stem-cell transplant for relapsed acute myeloid leukemia.

This article reviews the history and dermatologic side effects of alkylating agents used in chemotherapy, noting that some agents like chlorambucil can cause recurrent symptoms upon rechallenge, whereas others are tolerated.

This case report documents a young woman who experienced a visual field defect similar to those linked to vigabatrin use, despite treatment only with valproic acid and carbamazepine, suggestive of a possible metabolic vulnerability in certain patients with specific genetic backgrounds.

In the phase 3 CAPItello-291 trial, capivasertib combined with fulvestrant significantly increased progression-free survival in patients with advanced breast cancer with specific genetic alterations, but the authors highlight that managing side effects like diarrhea, rash, and hyperglycemia is crucial for optimizing treatment adherence and outcomes.

In this case study, a rare scalp arteriovenous fistula developed after hair transplantation in a 29-year-old male was successfully treated using endovascular embolization with platinum coils, resulting in symptom resolution and complete fistula disappearance without complications.

This case report observed vemurafenib-induced pityriasis amiantacea, a scalp scaling reaction, in a patient with metastatic melanoma, which was managed symptomatically without altering vemurafenib treatment.

This study reports that a single transplantation of autologous stromal vascular fraction significantly increased hair density and keratin score in androgenic alopecia patients within six months.

This study found that a new treatment candidate may effectively prevent and promote recovery from chemotherapy-induced alopecia by normalizing apoptosis and reducing inflammation in cancer patients.

This phase Ib study found that combining pegylated liposomal doxorubicin and pembrolizumab was well-tolerated and effective, with durable antitumor responses and a median survival of over two years in heavily pretreated ER-positive metastatic breast cancer patients.

In this analysis, safety data from two clinical trials showed that baricitinib for severe alopecia areata had predictable side effects like infections and elevated CPK, with some serious adverse events noted at low incidence rates; no deaths were reported.

This study reports on eight previously unpublished cases of Bohring-Opitz syndrome with ASXL1 mutations, suggesting the importance of screening for Wilms tumors in these patients.

In this case study, a 46-year-old post-transplant woman with poorly controlled diabetes exhibited a rare acquired form of epidermodysplasia verruciformis associated with HPV-49, marked by unique histological findings that distinguishing it from trichodysplasia spinulosa.

This study evaluated a new computer-aided detection system for identifying Breast Arterial Calcification in mammograms, achieving 70% accuracy, but highlighted the need for a larger dataset to explore its relationship with cardiovascular diseases.

This study found that 86% of patients with follicular non-Hodgkin's lymphoma were alive and nearly two-thirds remained in complete remission eight years after initial treatment with the radioimmunotherapy drug Bexxar.

This study identified known and potential novel adverse events, such as squamous cell carcinoma and dehydration, for vismodegib, underlining the importance of monitoring especially in the first two months of treatment.

This study found that lower expression of VDR protein in breast cancer patients is associated with increased bone metastasis and poorer prognosis, making it a significant prognostic factor.

This study found that arginine vasotocin is evolutionarily conserved across diverse taxa and may play roles in neuroendocrine, immune, and stress signaling, with potential antimicrobial applications.

This letter to the editor shares concerns about possible systemic effects from topical dinitrochlorobenzene therapy in a 25-year-old man treating alopecia areata.